With more than 110 researchers across Purdue University, the Purdue Center for Cancer Research (PCCR) has many of the greatest investigative talents in the world in one location. Since 1978, the Purdue University Center for Cancer Research has been a National Cancer Institute-designated basic research cancer center. Only seven institutions in the United States have earned this title. Being a basic research center means they don’t treat cancer patients directly. Their work focuses on investigating cancers where they begin — at the cellular level — to investigate the cause of and cure for one of the most devastating diseases of our time.
Doctors and scientists throughout the world use PCCR’s discoveries for treating cancer and to develop methods, medicines, and medical devices that together save and enhance patients’ lives.
Fostering a collaborative research community, the PCCR is the connector for both Purdue University and cancer research partners. Investigators from the Center’s Research Programs can access shared resources that include facilities, collaborative partnerships, and equipment alongside the ability to collaborate and interact with other researchers in multiple disciplines. The center is led by Dr. Timothy Ratliff, Robert Wallace Miller Director and Distinguished Professor of Comparative Pathobiology. Ratliff explains, “PCCR has a fundamental approach to discover new information about cancer that will lead to new ways to detect and treat the disease. Our scientists have developed new treatments for prostate, ovarian, endometrial, lung, kidney and colon cancers that are being tested now in clinical trials.”
With world-leading developments and cutting-edge innovations happening at PCCR, there are many incredible milestones and successes to note:
· PCCR is responsible for 14 potential drugs in clinical trials and more than 40 compounds in preclinical development, making it a leader in drug development.
· Technology stemming from research at the center has generated 14 startup companies within the past five years alone.
· A Nobel Prize winning chemist was among the PCCR innovators creating chemical processes used in cancer treatments
· PCCR is a member of the Big Ten Cancer Research Consortium: “the Big Ten cancer centers have united to transform the conduct of cancer research through collaborative, hypothesis-driven, highly translational oncology trials that leverage the scientific and clinical expertise of Big Ten universities.”
· Purdue University and MIT are the only two NCI-centers at a major university without a medical school or hospital
· PRF’s Office of Technology Commercialization is ranked 6th in the world for U.S. Utility patents, many of which are cancer research and drug discoveries ready to license or commercialize.